The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 24, 2021
Filed:
May. 03, 2017
Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;
Université Paris Diderot—paris 7, Paris, FR;
Universite Paris 13—paris Nord, Villetaneuse, FR;
Assistance Publique—hopitaux DE Paris, Paris, FR;
Institut Pasteur, Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Sylvie Bay, Paris, FR;
Antonino Nicoletti, Paris, FR;
Dominique Le Guludec, Paris, FR;
Jonathan Vigne, Paris, FR;
Giuseppina Caligiuri, Paris, FR;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris, FR;
UNIVERSITE DE PARIS, Paris, FR;
UNIVERSITE PARIS 13—PARIS NORD, Villentaneuse, FR;
ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris, FR;
INSTITUT PASTEUR, Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
Abstract
Disclosed is CD31for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31ligand in different rat models of inflammation indeed showed that CD31is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.